Welcome to Regeneron's conference call to discuss its C5 Complement Development Program. My name is Shannon, and I will be your operator for today's call. [Operator Instructions] Please note that this ...

BURNABY — The president of the BC Nurses’ Union says she’s expecting a strike vote in the coming weeks after contract talks involving about 55,000 nurses in the province broke off on Monday. Adriane ...

COLORADO SPRINGS, Colo. — Colorado Springs-based Ent Credit Union has officially changed its name to Wings Credit Union. The name change comes after Ent Credit Union ($9.9 billion, 560,000 members) ...

STOUGHTON, Wis. (WKOW) -- Food production workers at B&G Foods have voted to authorize a strike. Members of Teamsters Local 120 said they are fighting for fair wages, affordable health care and ...

The NYU Langone-Sage NDHCC will expand upon the work Sage Bionetworks has been doing for more than a decade, building infrastructure that makes collaborative biomedical research possible at scale.” — ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Downtown San Francisco's most ...

You can’t say we weren’t warned. Donald Trump himself forecast the epic length of the State of the Union address that he planned to deliver to Congress on Tuesday evening. “It’s gonna be a long speech ...

Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...

A Crew Dragon spacecraft docked with the International Space Station on Valentine’s Day, and astronauts popped open the hatches at 5:14 pm ET (22:14 UTC) on Saturday evening. The arrival of four new ...

WASHINGTON — Two people are in custody after a shooting on Massachusetts Avenue, Northeast that caused a calamity around Union Station Friday afternoon. DC police haven't released any information ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...